Effects of Hormone Replacement Therapy on Cardiovascular Risk and Body Composition Parameters
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Menopause is defined as the last episode of menstrual bleeding, resulting from the
interruption of ovarian function by follicular depletion. It is characterized by the presence
of amenorrhea associated with increased levels of FSH and low levels of estradiol. The
decline in estrogenic levels is associated with several organic changes, from vasomotor
symptoms to impaired bone mass and urogenital atrophy. Although for some patients menopause
is asymptomatic or oligosymptomatic, many women experience intense symptoms, which profoundly
affect quality of life.
Proper assessment and treatment of postmenopausal women can significantly improve climacteric
symptoms. Target tissue, hormone therapy regimen and variations between patients will
influence the effects of treatment. Regarding estrogen, the main factors that influence the
therapeutic response are the type of hormone used, the dose and the route of administration.
The skin metabolizes only a small part of estradiol. Thus, the transdermal route reaches
adequate therapeutic levels from a lower dose of estrogen.
The present study aims to evaluate and compare the effects of low dose of oral estradiol
associated with oral progesterone and transdermal estradiol associated with vaginal
progesterone on variables related to inflammation, coagulation and body composition
parameters.